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 ABSTRACT 
 
Vaccines are one of the most economically effective courses of preventative 
medicine and their efficacy has been proven in the eradication of many deadly, 
infectious diseases [3].  Despite their success in developed nations, the World Health 
Organization estimates that 2.5 million children worldwide still die of vaccine-
preventable diseases and of these children 70% are in the world’s poorest nations.  
Among the many vaccine strategies, glycoconjugate vaccines are an effective method, 
however their high cost of development and manufacture makes them inaccessible to 
developing nations.  Thus, the main goal of this research is to employ bacteria for the 
development of low-cost glycoconjugate vesicle vaccines.  A vesicle vaccine takes 
advantage of the inherent immunostimulatory properties of the components naturally 
found in the outer membrane which are included when parts of the outer membrane 
bleb off as outer membrane vesicles, or OMVs.  We hypothesize that glycoconjugate 
vesicle vaccines will address many of the current challenges surrounding 
glycoconjugate vaccines and make them attainable worldwide.  This research has 
shown that we can produce two types of glycoconjugate vaccines.  One variation is the 
conjugation of heterologous bacterial polysaccharides to lipid A, an adjuvant yet toxic 
component of lipopolysaccharide, or LPS, which is a major component of OMVs.  
The second variation is to utilize a conjugating enzyme, an oligosaccharyltransferase 
(OST), from the bacterium Camphylobacter jejuni to attach the bacterial 
polysaccharide to an outer membrane protein, which will bleb off with the outer 
membrane vesicles.  Both techniques utilize the stability and delivery benefits of 
bacterial outer membrane vesicles. This research has the potential to offer a stable, 
immunogenic, non-toxic, all-in-one vaccine and delivery system that may offer 
  ii 
protection against diverse infectious diseases that is inexpensive and accessible to 
developing nations. 
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CHAPTER 1:  INTRODUCTION 
 
Conjugate Vaccines & Immune Response 
The clinical goal of vaccines is to induce an immune response that will lead to 
the continuous production of antibodies against an infection by introducing all or part 
of an infection carrier to a host.  This is achieved by stimulating both lymphocytes 
from bone marrow (B cells) and lymphocytes that matured in the thymus (T cells).  
Our focus is on glycoconjugate vaccines, which are a bipartite structure consisting of 
an infectious bacterial antigen conjugated to an adjuvant carrier.  The purpose of the 
adjuvant is to enhance the immune response while the antigen is the component 
specific to a pathogen that will be recognized by the immune system should the 
infection be encountered post immunization.  Polysaccharides are often very specific 
to bacterial and viral species thus they make good antigen candidates.  Adjuvants are 
immunostimulatory specifically in activating both B cell and T cell response.  Toxins 
from bacteria are often used as adjuvants because they often have properties that the 
immune systems responds to in a way that gives rise to immunological memory. 
 Proteins are known to elicit a T cell dependent response directly, and are used 
in current glycoconjugate vaccine technologies [5]. When both a protein and 
polysaccharide are conjugated together and introduced to a host, the immune system 
recognizes the foreign body and presents the protein to T cells, which then become 
active.  The B cells immediately produce short-term antibodies against the 
polysaccharide as they would have if there been no protein conjugation.  The T cell 
involvement leads to the development of memory B cells that will produce active 
serum antibodies against the bacteria-specific polysaccharide, which are necessary 
should that bacterial infection be encountered in the future [5, 6].  An indirect way to 
activate the immune system is to use an adjuvant that induces macrophage activation.  
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Once a macrophage digests a foreign toxin, antigen-presenting cells then take those 
components that ultimately lead to the stimulation of T cells [7].  
A successful example of a glycoconjugate vaccine is the Haemophilus 
influenzae type b, or Hib, vaccine [5, 8, 9].  The Hib vaccine uses a capsular 
polysaccharide from the surface of the bacterium, which is chemically cross-linked to 
a protein.  Typically, the protein is a tetanus toxoid, diphtheria toxoid, diphtheria 
protein, or a protein complex from Neisseria meningitidis, all of which are highly 
immunogenic, or stimulate an active immune response [8]. This vaccine has 
drastically reduced the incidence of this bacterial infection in developed countries 
[10]. 
 
Current Methods for Conjugate Vaccine Production 
Unfortunately, current methods for producing conjugate vaccines are 
inefficient, very expensive, introduce toxic chemicals and allergens, and require the 
handling of dangerous pathogens to grow and isolate the bacterial polysaccharides [11, 
12].  There have been methods presented for synthetic formation of Hib vaccines via 
chemical synthesis of the polysaccharide antigen however these methods run into 
similar issues with the introduction of toxins used to modify the proteins and sugars 
for cross-linking [9, 11].  One way to conjugate a polysaccharide to a protein, 
according to current methods to produce the Hib vaccine, involves the use of 
cyanogen bromide, which modifies protein structures for conjugation, and is 
extremely poisonous [8]. In addition to the chemicals used, the production of 
conjugate vaccines is very lengthy requiring at least eight purification and 
modification steps as shown in Figure 1.  Lengthy procedures and the use of chemicals 
inevitably drive up the costs of production.  
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Figure 1:  Current methods of conjugate vaccine production.  (a) 
demonstrates the current methods for producing the Hib vaccine.  A 
pathogen must be grown so that the capsular polysaccharide may be 
isolated and modified for cross-linking.  The protein antigen is produced 
in a separate culture and is also isolated and modified before chemical 
cross-linking.  (b) is the current technology being used by GlycoVaxyn 
where all steps are done in vivo reducing the processing to a single culture 
and purification step.   
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Lipopolysaccharide  
Lipopolysaccharide (LPS) is a structure that is attached to the outer leaflet of 
the outer membrane in gram-negative bacteria.  LPS is comprised of lipid A, core 
sugars, and O-antigens as shown in Figure 2.  Lipid A anchors the molecule by 
extending into the outer membrane; attached to lipid A are the core sugars. The core 
sugars are comprised of 3-deoxy-D-manno-octulosonic acid (Kdo) sugars which are 
considered to be the minimal sugar necessary in LPS for E. coli to be viable [13, 14].  
O-antigen polysaccharides are the outermost part of LPS, connected to the core sugars 
[15].  Lipid A is an endotoxin, or bacteria-associated toxin, that causes septic shock 
which can lead to death [15, 16].  The immune system is so responsive to lipid A that 
the molecule induces the immune system to overproduce the molecules that are 
associated with the inflammatory response, which causes the sepsis [7].  Lipid A is 
mostly conserved among bacterial species, whereas the sugars become increasingly 
varied moving away from lipid A [17].  O-antigen polysaccharides are the most 
diverse component of LPS among bacteria and are specific to a bacterial species.  
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Figure 2: Structure of LPS.  Taken from Nagy et al [2].  
Note the three major components: lipid A or endotoxin, the 
core sugars, and the O-antigen.  
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Bacterial O-Antigens 
O-antigen construction starts on the inner leaflet of the inner membrane in the 
cytoplasm, a series of glycosyltransferases attach many sugar subunits, which are to be 
flipped to the periplasmic side by Wzx flippase [17].  The O-antigen ligase, which 
attaches an O-antigen molecule to the core sugars, is catalyzed by WaaL [18].  O-
antigens are common in pathogenic gram-negative bacteria, and due to their 
specificity to bacterial species they important molecules in designing safe, effective 
vaccines.  Because O-antigens are so unique to a species, the immune system is able to 
create serum antibodies that are very specific will be able to recognize the pathogen 
based on its polysaccharides in the future.   Additionally, a great advantage of using 
O-antigens for vaccine development and implementation is that the genes involved in 
the synthesis exist in clusters in the genome and thus can be isolated and cloned, 
eliminating the need to handle pathogens.  This increases the safety for all those who 
are involved in the research and production of these vaccines.  
Unfortunately, O-antigens alone cannot be used as vaccines as they elicit a T 
cell independent response, which means T cells are not stimulated [5].  B cells initially 
are stimulated to create antibodies against the O-antigen, but they are not continually 
produced in the serum and thus the immune system would not recognize these 
molecules if they were to be encountered again.  Memory B cells, which continually 
produce antibodies, are not created without T cell activation and hence there is no 
protection upon repeated exposure to the same pathogen.  Use of a polysaccharide-
only vaccine is also problematic and limited because of various immune disorders and 
children are not able to produce antibodies against polysaccharides until they are 
around 5 years of age.  Because younger children are more susceptible to disease, a 
polysaccharide-only vaccine would not be very useful.  
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A new adjuvant 3-O-desacyl-4’-monophosphoryl lipid A (MPL) has been 
FDA-approved for vaccines [19].  This structure is of interest to our work as this 
molecule is a similar structure to the lipid A found in most gram-negative bacteria 
such as E. coli.  Studies have shown that MPL is involved in cellular immunity, 
recruiting macrophages to break down the components of the foreign body [4]. It is 
believed that this adjuvant is involved in activating cytokine cascades and antigen 
presenting cells [20].  The antigen presenting cells then present the antigens to the T 
cells necessary for immunologic memory and MPL has actually been shown to 
inactivate suppressor T cells [21].  MPL is derived from the Salmonella minnesota 
lipid A where it is purified then chemically modified [20].  The first modification was 
discovered by Ribi et al [22].  They found that the removal of a phosphate group from 
the lipid A disaccharide reduced the toxicity of lipid A at least 100 fold.  However, the 
reduction in toxicity did not result in a loss of lipid A’s adjuvant properties.  In 
addition to this simple modification, it was discovered that removing an ester-linked 
fatty acid group even further reduced the toxicity of the molecule while retaining 
immunostimulatory properties [23].   
 
Outer Membrane Vesicles 
Outer membrane vesicles (OMVs) are non-replicating components of both 
virulent and non-virulent gram-negative bacteria.  They are comprised of outer 
membrane lipids, outer membrane proteins, LPS, and soluble periplasmic components, 
which are compartmentalized into the lumen [24, 25].  Figure 4 illustrates how outer 
membrane vesicles bleb off the surface of a cell.  Because vesicles contain sugars, 
proteins, and lipids, all of which are foreign to a mammalian host, vesicles themselves 
have been found to be highly immunogenic [26].  
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OMVs may serve as an appropriate vaccine delivery system because, as 
several recent studies have shown, mammalian cells internalize them [27, 28], which 
will be important for delivering vaccine components throughout the body.  
Additionally, OMVs of infectious bacteria have been found in the fluids of hosts, 
suggesting that they are much more permeable than larger bacterial components, 
delivering their components throughout a host [29].  One study focused on 
enterotoxigenic Escherichia coli (ETEC), which is a cause of traveler’s diarrhea, and 
the delivery of certain toxins into eukaryotic cells via vesicles.  It was discovered that 
hosts show elevated levels of heat-labile enterotoxin  (LT), which is involved in the 
attachment of the vesicles to mammalian cells through an interaction with a host 
surface receptor, GM1 [28, 30].  Another similar study showed that LT is actually 
enriched in OMVs and suggested that OMVs are a pathogenesis mechanism for ETEC 
[31].   Additionally in the same study, it was discovered that these vesicles deliver 
their components into the cell after internalization [28].  Another group similarly 
showed that vesicles from Pseudomonas aeruginosa, a pathogen that is common in 
cystic fibrosis and other immuno-compromised patients, are internalized into lung 
tissue to deliver proteases [27].  A curious phenomenon that occurs with vesicles is the 
enrichment of certain proteins such as virulence factors, toxins, adhesins, hemolysins, 
and proteases [31, 32].    It is hypothesized that once OMVs are internalized they are 
eventually trafficked to the endoplasmic reticulum where the proteins are then released 
into the cytosol as a method for delivering their toxins [29]. This evidence suggests 
that vesicles may be important in the infection process [24, 25, 33] and that they could 
be carriers and delivery systems for vaccine components. 
It has been demonstrated that OMVs may be engineered to include 
recombinant proteins in the lumen as well as in the membrane of the vesicles [24, 32]. 
Kesty et al showed that Ail, an adhesin from Yersinia enterocolitica, could be 
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expressed and incorporated into E. coli OMVs as shown in Figure 3 [24].  Kim et al 
showed that the outer membrane hemolysin, ClyA, could be fused with GFP and 
display fully functional GFP on the surface of OMVs [32].  ClyA was chosen based on 
research that showed that ClyA is naturally enriched in OMVs [34]. The ability to 
engineer OMVs is critical for the advancement of glycoconjugate vesicle vaccines. 
Figure 3:  Outer Membrane Vesicle production.  Vesicles are formed when 
the outer membrane blebs and pinches off to create a new vesicle.  We have 
shown that we can express recombinant membrane proteins to localize into 
these vesicle structures.  
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As demonstrated recently by Chen et al [35], OMVs containing recombinant 
green fluorescent protein (GFP) fused to ClyA can elicit a potent immune response in 
mice; whereas exposure to GFP alone without the OMV carrier results in a weak 
response.  ClyA-GFP fusion proteins alone also elicited an immune response, but 
required more protein than did the ClyA-GFP proteins that were in OMVs.  The 
importance of this study showed that OMVs can able to be a carrier and facilitate 
protein purification and still retain the ability of ClyA-GFP to elicit an immune 
response against a GFP, which is normally undetected by the immune system.  
Recently, natural OMVs purified from a pathogen itself, Neisseria 
meningitidis, have been extensively studied and accepted as an effective vaccination 
option for meningitis serotype B [36-39].  These vaccine OMVs are purified through 
detergent extraction, which eliminates a majority of the LPS which in turn causes the 
vesicles to lose their structure [40] and to aggregate making them hard to quantify for 
dosage [41].  While this method reduces the LPS, it also reduces the amount of other 
immunogenic membrane components and the integrity of the OMVs, thus a small 
amount of the endotoxin must still remain in the OMVs [42].   
This vaccine has been successful in preventing outbreaks of meningitis in 
Norway, Cuba, and New Zeland [36, 37, 39, 43], but there are a variety of limitations.  
First of all, the bactericidal serum response is against PorA, which is a variable 
antigen; the expression of only one type of PorA results in protection against only a 
specific type of PorA antigen.  Mixtures of OMVs from N. meningitidis expressing a 
variety of PorA proteins as well as recombinant DNA techniques so that one strain 
expresses more than one PorA have been used to overcome this [44].   Some genetic 
engineering has also been done to optimize the current OMV vaccine technology.  N. 
meningitidis has been engineered to increase vesicle production as well as to address 
the challenges that are associated with the loss of LPS in the detergent extraction.  A 
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mutation to the LpxL1 gene has been shown to reduce LPS toxicity while still 
retaining adjuvant properties and eliminating the need to use detergent extraction.  
This opens up the opportunity to explore other purification methods, such as our 
method of ultracentrifugation [38, 45].  Finally, the optimization and engineering that 
has been performed up to date is very specific for this one pathogen. 
 
Oligosacchryltransferase, PglB, and its Function 
Previously thought to only occur in eukaryotes, a functional N-linked 
glycosylation locus has been discovered in C. jejuni [46, 47].   Szymanski et al were 
able to characterize this pgl (protein glycosylation) locus and identify homology of 
these genes to other known eukaryotic genes involved in protein glycosylation [46].  
OSTs catalyze the attachment of a lipid-linked sugar to an asparagine residue involved 
in a consensus amino acid sequence for glycosylation, or glycosylation site, Asn-Xaa-
Ser/Thr, on a nascent protein; Xaa stands for any amino acid except proline [48, 49].  
These genes have been shown to be functional in E. coli and are able to glycosylate 
proteins that we have engineered to include glycosylation tags.   
Further, it has also been proven that PglB is able to transfer O-antigen sugars 
onto proteins containing the consensus sequence [50].   Thus we can utilize this OST 
to attach our antigens to an adjuvant we have engineered for glycosylation.  This is of 
particular importance to our work because our goal is to attach antigens to outer 
membrane-bound adjuvants in vivo such that only OMV purification would be 
necessary to purify the vaccine components. 
One hurdle of engineering sugar conjugation in E. coli is the competing, native 
reaction of O-antigen transfer by WaaL, which ligates O-antigens the lipid A-core 
sugar structure.  Feldman et al have discovered that in WaaL knockouts, where the 
competing reaction no longer occurs, PglB is able to transfer the O-antigens to protein 
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[50].  This technology is currently being used by a company, GlycoVaxyn, to produce 
conjugate vaccines in vivo. 
This Work 
OMV vaccines present a solution to a major drawback of current conjugate 
vaccine technology: their inaccessibility to developing countries both in terms of cost 
and implementation.  The high cost of these vaccines makes them hard to obtain 
without the aid of programs such as UNICEF [12].  Recently, the World Health 
Organization supported an anti-diarrheal vaccine, however health officials cited cost 
as a hindrance for universal vaccination for children. Conjugate vaccines are also very 
unstable, which may be problematic in areas where proper refrigeration may not be 
available.  Improper temperature storage as well as multiple freeze-thaw cycles 
degrades the protein and reduces the vaccine’s efficacy [12].   
Our work is to expand upon the current limited OMV technologies by using 
recombinant DNA techniques to create an OMV vaccine that are specific to a 
pathogen of our choosing.  We can engineer bacteria to produce OMVs that already 
carry highly immunogenic membrane proteins and lipid structures, to subsequently 
conjugate an antigen to an adjuvant in vivo.  We have studied two potential carriers 
that both have adjuvant properties.  One carrier is E. coli lipid A, the second is outer 
membrane proteins as described in Figure 4.     
We have engineered the E. coli membrane protein, ClyA, to contain four 
glycosylation sites at the C-terminus of the protein.  When this engineered protein is 
expressed in E. coli with pglB and the genes that encode the polysaccharide, a 
glycoprotein is detected in OMV fractions.  The antigen-adjuvant complex was 
created in vivo which greatly simplified the purification process to a single 
ultracentrifugation step.  Additionally we did not have to handle any pathogens or use 
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any toxic chemicals that are currently required for cross-linking antigens and 
protein adjuvants.  Choosing to glycosylate a membrane protein that 
localizes in OMVs builds upon the platform that GlycoVaxyn currently 
employs by facilitating purification.  OMV purification requires fewer steps 
than protein purification and can be purified from the supernatant.   
Additionally, given the approval of the lipid A derivative, MPL as an adjuvant, 
we studied the conjugation of O-antigens to lipid A.  We used lipid A in our 
preliminary work because it is already produced in E. coli; we are currently taking the 
Figure 4: Two ways of decorating OMVs with O-antigen 
polysaccharides.   (a) demonstrates how O-antigens (and N-glycans) are 
attached to the lipid A and the core sugars and then localize to the outer 
membrane by an unknown mechanism.  (b) depicts how protein 
glycosylation occurs in theory with the presence of pglB, a membrane 
protein engineered to include a glycosylation site, and if the competing, 
native reaction performed by WaaL is eliminated.  Both methods describe 
ways to localize lipid A and protein conjugated polysaccharides to the outer 
membrane where they can bleb off with vesicles. 
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next steps towards genetically modifying E. coli to have a structure more like MPL.  
Lab strains of E. coli already contain the ligation machinery necessary to conjugate O-
antigen to lipid A and thus E. coli only require the gene cluster of a heterologous O-
antigen. We have shown that we can decorate OMVs with many different O-antigens 
from many species.  
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CHAPTER 2:  MATERIALS AND METHODS 
 
Bacterial Strains and Plasmids  
 
Table 1: Plasmids used in this work 
 Description Source 
pClyA-Glyc-His6 ClyA-4 glycosylation sites-6 histidine tag, AmpR This work 
pPgl-wt pgl operon with pglB wt, CmR [51] 
pPgl-mut pgl operon with pglB mut, CmR [51] 
pLPS2 Pseudomonas aeruginosa O11 antigen gene cluster [52] 
pJHCV32 E. coli O7 antigen gene cluster [53] 
pSS37 Shigella dysenteriae O-antigen gene cluster [54] 
pPM2212 Shigella flexneri O-antigen gene cluster [55] 
pAY100 Yersinia enterocolitica O3 antigen gene cluster [56] 
pFTO3 Francisella tularensis O3 antigen gene cluster Rebecca Thomas 
 
Plasmid pClyA-Glyc-6His was constructed by ligating the PCR-amplified 
clyA gene into pTRC99-glyc-6His between SacI and XhoI sites. pTRC99-glyc-6His 
contains four repeating consensus sites necessary for glycosylation between XhoI and 
SalI sites as well as 6 histidines between SalI and HindIII sites.  The entire construct 
was then cut and ligated into pBAD18 using SacI and HindIII sites.  Plasmid pClyA-
Glyc-6His-pgl or pClyA-Glyc-6His-pglmut were constructed by PCR amplifying the 
clyA glyc- and histidine-tagged section of pClyA-Glyc-6His and ligating into 
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pBAD18 using SacI and XmaI sites.  pglB and pglB mut were cut and ligated using 
XmaI and SbfI sites. 
Table 2: Bacterial strains used in this work 
 Description Source 
JC8031 Hypervesiculating E. coli [57] 
CE8032 waaL::Kan, derived from JC8031 a 
hypervesiculating E. coli strain 
This work 
 
Strain CE8032 was made via P1 transduction by infecting JC8031 cells with 
P1 phage from the donor Keio waal::Kan.  
P1 Transduction 
P1 transduction is a method that takes advantage of a bacteriophage that 
packages genomic DNA into its capsule.  To achieve waaL knockouts, P1 phage 
transducing particles from Keio collection was used.  Overnights of the appropriate 
Keio strain (Keio waaL::Kan), were subcultured 1:100 into 2 mL LB, 5 mM CaCl2, 10 
mM MgSO4, 0.2% glucose for approximately 90 minutes at 37˚C, 225 rpm. 50 uL of 
P1 phage was added to the culture and incubate for 1-4 hours at 37˚C, 225 rpm.  After 
the cultures showed clearing, 10-20 uL of chloroform was added to kill any remaining 
cells, vortexed and allowed to incubate at room temperature for 10 minutes.  After 
transferring to a clean Eppendorf tube, the culture was spun for 10 minutes at 13,000 
rpm.  The supernatant containg the phage was collected.  600 uL of overnight of the 
recipient strain, JC8031, was spun down at 3000 rpm for 2-3 minutes. The cells were 
resuspended in 100 uL LB, 5 mM CaCl2, 10 mM MgSO4, and 0.2% glycose.  After 
adding100 uL of lysate, the mixture was incubated at 37˚C with gentile agitation. 
After 30 minutes, 100 uL of 1M sodium citrate and 1 mL of LB were added and 
allowed to shake for another hour. The cells were then spun down at 3000 rpm for 5 
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minutes and resuspended in 100 uL LB, 100 mM sodium citrate and plated on LB agar 
plates with Kanamyacin and 100 mM sodium citrate. 
Soybean Agglutinin Labeling 
Soybean agglutinin (SBA) conjugated to Alexa Fluor was used to test whether 
or not the knockouts were achieved by assessing the ability of SBA to attach to 
available N-glycan.  100 uL of overnight cultures containing pPgl were rinsed with 
PBS and resuspended in 10 µg/mL SBA dissolved in PBS. After incubating for an 
hour at room temperature, cells were rinsed again with PBS, resuspended in PBS, and 
analyzed using FACS. 
Preparation of OMVs 
OMVs were purified using the established procedure previously described by 
Kolling et al [58].  CE8032 was sequentially transformed first with pClyA-Glyc-His6 
and selected on LB-ampicillin plates.  These transformants were then transformed 
with pPgl-wt and pPgl-mut and selected on LB-ampicillin-chloramphenicol plates. 
Flasks with 50 mL LB media with ampicillin, chloramphenicol, and 0.2% glucose 
were inoculated with an overnight culture and allowed to grow at 30˚C until an OD600 
of ~0.4 was achieved.  To eliminate the glucose media, cultures were centrifuged for 
15 minutes at 3200 rpm, 4˚C.  Cell pellets were resuspended in 150 mL LB media 
with ampicillin, chloramphenicol, and 0.2% arabinose and grown at 30˚C overnight.  
After 10 hours of induction, cells were centrifuged at 7500 rpm, 20 minutes, 4˚C. 
Pellets were frozen for His purification.  The supernatants were then filtered through a 
0.45-µm filter to eliminate any remaining cells. OMV fractions were isolated by 
ultracentrifugation at 28,000 rpm for 3 hours at 4˚C (Beckman-Coulter; Ti SW28 
rotor).  Pellets were resuspended in PBS and stored at -20˚C. 
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Protein Purification 
Proteins were purified according to the Qiagen Ni-NTA Spin Kit instructions 
under native conditions.  Frozen cell pellets were resuspended in 1 mL lysis buffer 
supplemented with 1% (v/v) TritonX-100 and 1mg/mL lysozyme and incubated on ice 
for 30 minutes. Cells were sonicated 4 times for 30 seconds with a 1-minute rest.  The 
sonicated cells were spun down at 10,000g, 4˚C, 20 minutes. Supernatants were run 
over the columns, washed, and eluted with 250 mM imidazol.  
Western Blotting 
Both OMV and purified protein samples were analyzed using SDS/PAGE gels.  
Samples were prepared in the sample loading buffer with β-mercaptoethanol and 
boiled for 15 minutes at 100˚C.  Samples were then run on 12% polyacrylamide gels 
(BioRad, Mini-PROTEAN® TGX) in duplicate.  For western blotting, proteins were 
transferred onto nitrocellulose membranes and probed the appropriate primary 
antibody specific for the polysaccharide or anti-6xHis conjugated to HRP (1:5000). 
Membranes probed with anti-Hr6P were probed with anti-rabbit (1:2500) secondary 
antibody. 
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CHAPTER 3:  RESULTS 
 
Host Cell Engineering 
A waaL knockout in the vesiculating E. coli strain JC8031 was necessary for 
two reasons.  One, as described by Feldman et al, WaaL ligates bactoprenol-linked 
polysaccharides to lipid A [50].  Because bactoprenol-linked polysaccharides are the 
substrate that pglB uses, it is necessary to eliminate the competing reaction performed 
by waaL to increase the efficiency of the protein glycosylation performed by pglB.  
Secondly, we wanted to analyze whether or not the O-antigen ligase is in fact waaL 
and whether it has the ability to transfer a variety of polysaccharide structures.  
 To create the knockout, P1 transduction was utilized by making transducing 
phage with Keio waaL::Kan.  The transducing phage was used to infect JC8031 and 
the colonies that conferred Kanamyacin resistance were chosen.  In order to test the 
knockout, the Keio parent, Keio waaL::Kan, JC8031 and the putative JC8031 
waaL::Kan were transformed with the pgl operon which contains the genes that 
express the N-glycan.  These cells were grown overnight and labeled with SBA and 
analyzed using FACS.  Cells that have a functional WaaL will be able to transfer the 
N-glycan to the lipid A which subsequently localizes to the surface so that SBA can 
bind and label the cells for FACS analysis.  If the waaL knockouts were successful, 
the N-glycan cannot be transferred to lipid A and there would be no fluorescent signal.  
The results shown in Figure 5 show a loss in fluorescent signal in the JC8032 
waaL::Kan, renamed CE8032. 
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Figure 5: Knocking out waaL in JC8031.  FACS results measuring 
for fluorescence in SBA labeled cells.  All four panels represent 
different cell lines expressing the pgl operon.  The Keio parent and 
JC8031 show fluorescent signal as expected when N glycan is 
localized to the surface due to waaL ligation.  Keio waaL::Kan and 
JC8031 waaL::Kan show a loss in signal when waaL is knocked out 
and N glycan is not attached to lipid A before export to the outer 
membrane.  
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O-antigen Expression and Lipid A Conjugation 
 As described before, O-antigen sugar structures are widely varied across 
bacteria.  We received a variety of O-antigen gene clusters from various species.  It 
was important to test not only the expression of these antigens but if they could 
localize to OMVs.  All of the vectors were transformed into JC8031, grown, and OMV 
fractions were isolated and run on SDS-PAGE polyacrylamide gels.  Each antigen we 
tested had specific antiserum for western blotting.  As shown in Figure 6, we tested the 
N-glycan from C. jejuni, and the O-antigens from E. coli, Pseudomonas aeruginosa, 
Yersinia enterocolitica, Shigella dysenteriae, Shigella flexneri, and Francisella 
tularensis.  The first lanes of each blot are JC8031 expressing the empty vector that 
the O-antigen was cloned into or just OMVs isolated from JC8031, depending on 
whether or not we had the empty vectors.  The second lane in each blot is JC8031 
expressing the O-antigen genes.  Each example shows banding, which is very common 
in O-antigens as they are often polymers of repeating sugar structures.  
 We theorized that WaaL was responsible for attaching the polysaccharides to 
the lipid A.  In order to analyze whether or not WaaL has an integral part in attaching 
O-antigens and N glycan to create LPS, the O-antigen gene clusters were expressed in 
the waaL knockout strain CE8032.  If WaaL is responsible for attaching the O-antigen 
to complete the LPS structure, a knockout would result in a loss of antibody 
attachment in a blot because presumably the O-antigens had no way of localizing to 
the outer membrane or OMVs.  The third lane in all of the blots, except for in Figure 
6d (Y. enterolitica), is the O-antigen expressed in CE8032.  The cosmid for the Y. 
enterocolitica O-antigens would not express in CE8032.  The loss of antibody 
attachment in these lanes provides evidence that WaaL is in fact responsible for the 
attachment of O-antigen to complete the LPS structure.  This further implicates that 
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WaaL is promiscuous enough that it was able to recognize all of the O-antigen 
structures as a substrate and attach them to the core sugars.   
Figure 6: Lipid A conjugated N-glycan and O-antigens. All lanes represent 
OMV fractions and were western blotted with commercial antiserum specific 
for the polysaccharide being studied. (a) C. jejuni N glycan.  (b)  E. coli O7.  
(c) P. aeruginosa O11.  (d) Y. enterocolitica O3.  (e)  S. dysenteriae O-
antigen.  (f)  S. flexneri O-antigen.  (g)  F. tularensis  O-antigen.  In (a-g) the 
first lane is JC8031 cells with the empty vector that the polysaccharide genes 
were cloned into or JC8031 without any plasmid as indicated.  The second 
lane is JC8031 expressing N glycan or O-antigens.  The third lane in (a, b, c, 
e, f, g) is the waaL knockout expressing N glycan or O-antigens.  This lane is 
missing in (d) because the plasmid would not express.  
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Figure 6 (Continued) 
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Protein Conjugation 
 Proteins are known adjuvants and are a good target for O-antigen conjugation 
to produce a conjugate vaccine in vivo.  Thus, ClyA, a membrane protein that is a 
known adjuvant, was engineered to carry four glycosylation consensus sites, also 
known as a glyc site.  The ClyA was also engineered to include a 6x histidine residue 
for purification as well as western blot detection.  We expressed this engineered ClyA 
with the pgl operon, which includes the genes for making the N-glycan and pglB for 
transferring the N-glycan to a protein, in CE8032.  We also expressed the engineered 
ClyA with the pgl operon mutated, which has functional N-glycan synthesis genes, but 
a non-functional pglB.  CE8032 was chosen because it was a hypervesiculating E. coli 
Figure 7: Protein glycosylation in OMVs.  The first two lanes in (a) and (b) 
are OMV fractions where the pgl operon was expressed with either pglB wt or 
pglB mut as indicated with pClyA-Glyc-6His.  The anti-His blot demonstrates 
that both proteins expressed well.  The hR6P blot demonstrates that the N-
glycan is only present when there is a functional pglB.  The last two lanes in (a) 
and (b) are purified protein from whole cell lysates verifying that ClyA is in fact 
a glycoprotein when pglB is functional. 
  25 
that also had waaL knocked out.  In an attempt to maximize the glycosylation that 
occur, we wanted to use a waaL knockout to eliminate the competing, native reaction.  
The experiments that contained a pglB wt should show glycosylation on ClyA 
whereas the pglB mut should show none.  Glycosylation was detected using western 
blotting with antiserum specific for the N-glycan, anti-Hr6P.  Protein expression was 
detected using anti-6His.  The blot in Figure 7 shows both the OMV fractions as well 
as the purified protein from whole cell lysates.  The first two lanes in (a) and (b) are 
OMV fractions, with the first expressing pglB wt and the second expressing pglB mut.  
Based on these results, it is clear that the protein is expressing with bands appearing in 
both lanes in the anti-His blot.  The anti-Hr6P blot shows a distinctive banding pattern 
in the pglB wt and none in the pglB mut case showing that the pglB wt was functional 
in transferring N-glycan to the glyc tagged ClyA.  Further to be sure that the protein 
itself was being glycosylated the third and fourth lane are the purified protein from 
whole cell lysate using Ni-NTA columns.  Again, these results show that the protein 
was expressed well in both cases and showed that N-glycan was attached to these 
proteins in the pglB wt and not in the pglB mut experiment.  
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CHAPTER 4:  DISCUSSION 
 
The results from this work have shown that we can decorate OMVs with 
polysaccharides using two different conjugation methods that each have the potential 
to be vaccine candidates.  While OMVs are currently being used as vaccines and some 
genetic engineering has been done to optimize the process, those vaccines are only for 
meningitis serotype B and optimizations are very specific for OMVs produced by N. 
meningitidis [44, 45].  This work has been focused around developing a strategy for 
decorating OMVs with polysaccharides that can be universal and robust.  
We have shown that we can glycosylate and recover membrane proteins in 
vivo by isolating OMV fractions.  The in vivo glycosylation of antigens to protein 
adjuvants to make conjugate vaccines is currently being developed by the company 
GlycoVaxyn.  While their technology has simplified the conjugate vaccine production 
process to that shown in Figure 1b, the protein purification process is still costly and 
the product still needs to be properly stored or the proteins could degrade decreasing 
its efficacy [12].  Our work hopes to expand upon this technology by glycosylating 
membrane proteins.  By using a membrane protein that is embedded and protected in 
the outer membrane, we can potentially reduce the purification process to that of 
ultracentrifugation or ultrafiltration.  Furthermore, the OMV is a stable carrier for the 
glycoproteins as well.   
We have also shown that we can express a variety of O-antigens from various 
species in E. coli and that they do localize in OMVs.  Our system seems to be 
universal enough where many types of O-antigens are able to be expressed in E. coli 
and thus could imply that this could be a promising method.  Lipid A is known to be 
an adjuvant, but in certain quantities, is extremely toxic.  While some studies have 
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suggested that membrane-bound lipid A is less toxic than free lipid A, the current 
OMV vaccine technology for meningitis was developed using detergent extraction 
which eliminates much of the lipid A.  Because of the problems associated with 
detergent extracted OMVs, there is research being performed to find alternative 
purification methods while still ameliorating the toxic effects of lipid A.  Current 
information suggests that modified lipid A structures, such as MPL or LpxL1 mutants 
or knockouts, are an equally effective adjuvant at eliciting an antibody immune 
response while also being less toxic and can be purified using ultracentrifugation [20, 
45].    
We have proven that E. coli already contains the necessary ligase, WaaL to 
attach the O-antigens examples we tested onto lipid A.  We hope that because of the 
variety of antigens WaaL conjugated to lipid A, that this could be a universal method 
for creating antigens conjugated to the adjuvant lipid A.  In every O-antigen 
expressed, the host was the same non-pathogenic JC8031 E. coli strain.  In 
combination with the data we have generated and the information on modified lipid A 
structures, we could engineer a non-pathogenic E. coli to naturally produce modified 
lipid A structures that are already being used as adjuvants.  These E. coli should have 
the functionality to produce non-toxic, adjuvant lipid A structures but also retain its 
ability to conjugate O-antigens to these structures in vivo to create safe, effective 
OMV vaccines. 
We believe that our two conjugate vaccine methods gave the potential to be 
effective bacterial vaccines.  Both options attempt to optimize and facilitate the 
production of current vaccine technologies. By combining the current knowledge on 
OMV vaccines, modified lipid A structures as adjuvants, and conjugate vaccines, we 
believe we have presented a way to combine and optimize the best of each of these 
vaccine technologies.  
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CHAPTER 5: FUTURE WORK 
 
Our future work involves further developing these methods to create a new 
class of bacteria vaccine.  One aim is to engineer a host strain that produces OMVs 
that are non-toxic to humans yet still has adjuvant properties, carry O-antigens, and 
can elicit a proper immune response.  In order to further the results discussed here into 
a technology, we must optimize our OMVs to elicit the ideal immune response, 
expand the scope of our O-antigens, and to characterize OMVs. 
We would like to develop methods to clone gene clusters of O-antigens.  While 
we have received a diverse array of isolated O-antigens in vectors from collaborators, 
we are limited by the small fraction of O-antigen genes that have actually been 
isolated and cloned.  We would like to develop methods to be able to clone these gene 
clusters from genomic DNA of pathogens and be able to remove these expand the 
scope of expression of O-antigens.  Vibrio cholerae is one example of an O-antigen 
that would be of interest to express for vaccine development, but could not express 
from what we were given by collaborators.  This is an important method to develop 
not only because we could address any new pathogens that may arise, but because it 
would further prove our work as a method for expressing virtually any O-antigen in E. 
coli.  
Other optimization that should be performed is in finding an appropriate 
adjuvant protein carrier for the glycosylation of protein adjuvants.   We used ClyA as 
our model system because it is a known outer membrane protein and an adjuvant, but 
it is also a hemolytic protein [59], which in certain dosages may prove to be harmful to 
a patient.  ClyA mutants are being screened for their localization abilities as well as if 
they retain their adjuvant properties.  Additionally, the location of the glycosylation 
site should be studied.  At this time, it is unknown if the glycosylated segment of the 
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protein is outside the vesicle or in the lumen.  Further characterization should be 
performed to analyze whether or not the adjuvant-antigen complex would be effective 
given the current glycosylation site.  We would want to optimize not only the protein 
but the location of the antigens. 
One way we propose to reduce the toxicity of our OMVs is to mutate or 
knockout specific genes involved in lipid A synthesis that would eliminate any toxic 
effects.  A screen should be done to identify candidates for genetic knockouts or 
modifications that could mitigate the toxicity of lipid A while retaining its adjuvant 
properties. For example, LpxL1 knockouts in N. meningitis, have already been 
identified as a potential target [45].  Further, understanding lipid A synthesis and the 
genes involved could be another way to alter the E. coli lipid A so that it is non-toxic. 
In addition to screening E. coli mutants for less toxic lipid A, another possibility 
would be genetically modify E. coli to knockout certain lipid A construction steps in 
order to create an MPL-like structure in vivo.  The difference between the E. coli lipid 
A structure and the MPL structure is shown in Figure 8. Various bacteria, such as 
Helicobacter pylori and F. tularensis, modify their lipid A structures in order to evade 
the human immune system [60, 61], thus there are enzymes that could perform these 
modifications in E. coli. A major difference between E. coli lipid A and non-toxic 
MPL is a single phosphate group.  Both H. pylori and F. tularensis modify their lipid 
A with enzymes that cleave the phosphate group that would make E. coli lipid A more 
chemically similar to MPL [60, 62].  If we can delete the genes for the enzyme that is 
responsible for adding that phosphate group it would eliminate any post-purification 
detoxification that is currently used to create MPL. 
 In addition to trying to engineer E. coli to produce non-toxic lipid A, we are 
looking into other forms of E. coli as our host strain.  Recently we discovered that we 
can engineer an E. coli that was isolated from human intestines, Nissle1917, to 
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vesiculate.  Because these bacteria live naturally in human intestines, we hypothesized 
that these E. coli are somehow not as toxic to our systems as lab strains of E. coli 
would be, but this has not been tested.  Nissle1917 has the same E. coli lipid A 
structure so it still could be possible that these strains would require more engineering 
to alter their lipid A structures as previously discussed.   
Experiments are currently being performed to analyze the difference in 
immune response in mice of OMVs and LPS with the same O-antigen attached.   We 
hypothesized that because the OMVs have many other components that could serve as 
adjuvants that the OMVs could potentially reduce the total amount of lipid A that must 
be administered to elicit an immune response.  If these experiments prove that OMVs 
can elicit more antibodies than the same effective does of lipid A in LPS, this could be 
a first step towards proving lipid A, or modified lipid A, conjugated vaccines could be 
effective. 
 All of the future work proposed aims to create OMVs that can be produced in 
vivo to reduce processing steps and to eliminate the need to handle pathogens.  Our 
Figure 8: E. coli lipid A and MPL. (a) depicts the E. coli lipid A structure [1] 
(b) depicts the MPL structure [4] 
 
a b 
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aim is to ultimately develop an OMV vaccine technology that will be widely universal 
and that exploits the benefits of vesicles to create a cheap, effective, accessible 
vaccine. 
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